Abstract: Material properties are manipulated using rapid pulse application of energy in combination with applied electric or magnetic fields. When sintering, annealing or crystallizing a target film, the pulse repetition cycle can be constrained to ensure material temperature rises above and falls below the Curie temperature before the next energy pulse. This process results in enhanced material properties as compared to traditional techniques having a single, slow temperature excursion and subsequent application of the applied external field.

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.

Abstract: The present invention belongs to the field of material preparation, and particularly relates to a two-dimensional clay based composite phosphorus removing agent and a preparation method. The two-dimensional clay based composite phosphorus removing agent provided by the present invention takes two-dimensional clay, hydroxide (such as lanthanum hydroxide, calcium hydroxide, magnesium hydroxide and aluminum hydroxide) and urea as raw materials, and the composite phosphorus removing agent with high property is prepared by a roasting method. Through a combined physical and chemical method, phosphorus in the phosphorus-containing wastewater is effectively removed by the synergic interaction between components of the composite phosphorus removing agent.

Abstract: The present disclosure discloses a drip hose, comprising a hose body and a drip head inner plug. A sealing post is fixed in the opening of the hose body, a sealing ring is fixed in the interior of the drip head inner plug, the drip head inner plug is capped in the hose body, the sealing post blocks the sealing ring, the sealing post, the sealing ring and the drip head inner plug jointly form a storage space; a small liquid outlet aperture is arranged in the sealing ring, and a small liquid outlet hole is arranged in the head of the drip head inner plug, and the small liquid outlet aperture is in communication with both the storage space and the opening of the hose body.

Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.

Abstract: The present invention belongs to the field of material preparation, and particularly relates to a two-dimensional clay based composite phosphorus removing agent and a preparation method. The two-dimensional clay based composite phosphorus removing agent provided by the present invention takes two-dimensional clay, hydroxide (such as lanthanum hydroxide, calcium hydroxide, magnesium hydroxide and aluminum hydroxide) and urea as raw materials, and the composite phosphorus removing agent with high property is prepared by a roasting method. Through a combined physical and chemical method, phosphorus in the phosphorus-containing wastewater is effectively removed by the synergic interaction between components of the composite phosphorus removing agent.

Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.

Abstract: The present invention belongs to the field of medical materials. A nano-oxide/kaolin composite hemostatic antibacterial material includes an iron oxide/kaolin composite carrier, and zinc oxide supported on the surface of the composite carrier. The present invention further provides the preparation and application of the composite hemostatic antibacterial material. Furthermore, the present invention provides a hemostatic healing-promoting dressing including the composite hemostatic antibacterial material disclosed by the present invention. The present invention surprisingly finds from research that the zinc oxide and iron oxide/kaolin composite carrier have a synergistic effect, and further cooperated with a special loading morphology, the synergistic effect of the two is unexpectedly enhanced, the hemostatic property and antibacterial property of the material are effectively improved, and moreover, the rate of wound healing is further improved.

Abstract: The present disclosure discloses a drip hose, comprising a hose body and a drip head inner plug. A sealing post is fixed in the opening of the hose body, a sealing ring is fixed in the interior of the drip head inner plug, the drip head inner plug is capped in the hose body, the sealing post blocks the sealing ring, the sealing post, the sealing ring and the drip head inner plug jointly form a storage space; a small liquid outlet aperture is arranged in the sealing ring, and a small liquid outlet hole is arranged in the head of the drip head inner plug, and the small liquid outlet aperture is in communication with both the storage space and the opening of the hose body.

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

Abstract: The present invention is based, in part, on the discovery of anti-galectm-1 (Gal 1.) monodonai antibodies useful for diagnostic and prognostic applications, as well as immunoglobulins, polypeptides, and nucleic acids thereof.

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.

Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.

Abstract: Material properties are manipulated using rapid pulse application of energy in combination with applied electric or magnetic fields. When sintering, annealing or crystallizing a target film, the pulse repetition cycle can be constrained to ensure material temperature rises above and falls below the Curie temperature before the next energy pulse. This process results in enhanced material properties as compared to traditional techniques having a single, slow temperature excursion and subsequent application of the applied external field.

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.

Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.